Tin tức & Cập nhật

In a prespecified secondary analysis of the phase III FLOW trial, semaglutide reduces the risk of serious infections and COVID-19 events in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Therapeutic-dose anticoagulation has contributed to a decrease in the likelihood of organ support or death among noncritically ill hospitalized patients with COVID-19. Such experience shows how quick and rigorous approaches, when aligned, can promptly translate evidence into practice, suggests a study.